33
- Allum WH, Stenning SP, Bancewicz J, Clark
PI, Langley RE (2009) Long-term results of a
randomized trial of surgery with or without
preoperative chemotherapy in esophageal can-
cer. J Clin Oncol 27:5062–5067
- Urschel JD, Vasan H (2003) A meta-analysis of
randomized controlled trials that compared
neoadjuvant chemoradiation and surgery to
surgery alone for resectable esophageal cancer.
Am J Surg 185:538–543
- Gebski V, Burmeister B, Smithers BM, Foo K,
Zalcberg J, Simes J, Australasian Gastro-
Intestinal Trials Group (2007) Survival benefits
from neoadjuvant chemoradiotherapy or che-
motherapy in oesophageal carcinoma: a meta-
analysis. Lancet Oncol 8:226–234
- Sjoquist KM, Burmeister BH, Smithers BM,
Zalcberg JR, Simes RJ, Barbour A, Gebski V,
Australasian Gastro-Intestinal Trials Group
(2011) Survival after neoadjuvant chemother-
apy or chemoradiotherapy for resectable
oesophageal carcinoma: an updated meta-
analysis. Lancet Oncol 12:681–692
- Cunningham D, Allum WH, Stenning SP,
Thompson JN, Van de Velde CJ, Nicolson M,
Scarffe JH, Lofts FJ, Falk SJ, Iveson TJ, Smith
DB, Langley RE, Verma M, Weeden S, Chua
YJ, MAGIC Trial Participants (2006)
Perioperative chemotherapy versus surgery
alone for resectable gastroesophageal cancer. N
Engl J Med 355:11–20
- Ychou M, Boige V, Pignon JP, Conroy T,
Bouché O, Lebreton G, Ducourtieux M,
Bedenne L, Fabre JM, Saint-Aubert B, Genève
J, Lasser P, Rougier P (2011) Perioperative
chemotherapy compared with surgery alone for
resectable gastroesophageal adenocarcinoma:
an FNCLCC and FFCD multicenter phase III
trial. J Clin Oncol 29:1715–1721
- Al-Batran SE, Hofheinz RD, Pauligk C et al
(2016) Histopathological regression after neo-
adjuvant docetaxel, oxaliplatin, fluorouracil,
and leucovorin versus epirubicin, cisplatin, and
fluorouracil or capecitabine in patients with
resectable gastric or gastro-oesophageal junc-
tion adenocarcinoma (FLOT4-AIO): results
from the phase 2 part of a multicentre, open-
label, randomised phase 2/3 trial. Lancet
Oncol 17:1697–1708
- MacDonald JS, Smalley SR, Benedetti J et al
(2001) Chemoradiotherapy after surgery com-
pared with surgery alone for adenocarcinoma
of the stomach or gastroesophageal junction. N
Engl J Med 345:725–730
- Smalley SR, Benedetti JK, Haller DG (2012)
Updated analysis of SWOG-directed inter-
group study 0116: a phase III trial of adjuvant
radiochemotherapy versus observation after
curative gastric cancer resection. J Clin Oncol
30:2327–2333
- Sakuramoto S, Sasako M, Yamaguchi T et al
(2008) Adjuvant chemotherapy for gastric can-
cer with S-1, an oral fluoropyrimidine. N Engl
J Med 357:1810–1820
- Sasako M, Sakuramoto S, Katai H et al (2011)
Five-year outcomes of a randomized phase III
trial comparing adjuvant chemotherapy with
S-1 versus surgery alone in stage II or III gas-
tric cancer. J Clin Oncol 29:4387–4393
- Bang YJ, Kim YW, Yang HK et al (2012)
Adjuvant capecitabine and oxaliplatin for gas-
tric cancer after D2 gastrectomy (CLASSIC): a
phase 3 open-label, randomised controlled
trial. Lancet 379:315–321
- Noh SH, Park SR, Yang HK et al (2014)
Adjuvant capecitabine plus oxaliplatin for gas-
tric cancer after D2 gastrectomy (CLASSIC):
5-year follow-up of an open-label, randomised
phase 3 trial. Lancet Oncol 15:1389–1396
- Lasithiotakis K, Antoniou SA, Antoniou GA
et al (2014) Gastrectomy for stage IV gastric
cancer. A systematic review and meta-analysis.
Anticancer Res 34:2079–2085
- Wagner AD, Grothe W, Haerting J et al (2006)
Chemotherapy in advanced gastric cancer: a
systematic review and meta-analysis based on
aggregate data. J Clin Oncol 24:2903–2909
- Wagner AD, Unverzagt S, Grothe W, Kleber
G, Grothey A, Haerting J, Fleig WE (2010)
Chemotherapy for advanced gastric cancer.
Cochrane Database Syst Rev 17:CD004064
- Blum JL (2000) The role of capecitabine, an
oral, enzymatically activated fluoropyrimidine,
in the treatment of metastatic breast cancer.
Oncologist 6:56–64
- Cunningham D, Starling N, Rao S et al (2008)
Capecitabine and oxaliplatin for advanced
esophagogastric cancer. N Engl J Med
358:36–46
- Kang YK, Kang WK, Shin DB et al (2009)
Capecitabine/cisplatin versus 5-fluorouracil/
cisplatin as first-line therapy in patients with
advanced gastric cancer: a randomised phase III
noninferiority trial. Ann Oncol 20:666–673
- Chap LI, Laux I, VanVugt A et al (2008) A
phase I study of S-1 GI toxicity with and with-
out oxonic acid (Oxo). J Clin Oncol 26:623s.
(abstr 13539)
- Saif MW, Rosen LS, Zhang J et al (2008) A
phase I study evaluating the effect of CDHP as
a component of S-1 on the pharmacokinetics
(PK) of 5-fluorouracil (5-FU). J Clin Oncol
26:115s. (abstr 2514)
Chemotherapy
